Compare INUV & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | ITRM |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 24.3M |
| IPO Year | 1996 | 2018 |
| Metric | INUV | ITRM |
|---|---|---|
| Price | $1.89 | $0.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $11.00 | $9.00 |
| AVG Volume (30 Days) | 202.8K | ★ 30.9M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.36 | $0.03 |
| 52 Week High | $6.27 | $1.16 |
| Indicator | INUV | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 26.10 |
| Support Level | $1.82 | N/A |
| Resistance Level | $1.99 | $0.39 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 27.03 | 3.34 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.